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ABSTRACT
Background. Masked uncontrolled hypertension (MUCH) is
associated with greater target organ damage such as left ventric-
ular hypertrophy, increased arterial stiffness and albuminuria.
Whether MUCH independently associates with greater cardio-
vascular end-organ damage or kidney damage is unclear. The
objective of this study was to assess the strength of the relation-
ship of MUCH (awake ambulatory blood pressure 135/85
mmHg and clinic blood pressure <140/90 mmHg) with target
organ damage.
Methods. In a cross-sectional study at a veterans’ administra-
tion medical center, clinically normotensive veterans without
chronic kidney disease (CKD) (n ¼ 29) and 287 patients with||
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|CKD and controlled hypertension (CH, n ¼ 193), MUCH (n ¼
67) and uncontrolled hypertension (UCH, n ¼ 27) had evalua-
tion of target organ damage. Target organ damage was meas-
ured by echocardiography [left ventricular mass index (LVMI)],
arterial ultrasonography [aortic pulse wave velocity (PWV)]
and 24-h urine collection [albuminuria (urine albumin to creati-
nine ratio)] in all participants.
Results. Compared to that of controls, LVMI was higher by
21.8 g/m2 (CI, 4.0–39.7 g/m2) in CH, 27.9 (CI, 8–47.8) in
MUCH and 39.5 (CI, 15.7–63.2) in UCH (P < 0.01 for group
differences, P< 0.01 for linear trend). Although differences per-
sisted after adjustment for age, sex and race, they lost signiﬁ-
cance after adjustments for cardiovascular risk factors and their
treatment. Compared to that of controls, PWV was different
among CH, MUCH and UCH (P ¼ 0.04 for group differences,
P¼ 0.02 for linear trend). However, differences lost signiﬁcance
after adjustments for age, sex and race. Compared to that of
controls, log2 UACR was higher by 2.40 mg/mg (CI, 1.28–3.52)
in CH, 4.94 (CI, 3.70–6.18) in MUCH and 6.01 (CI, 4.49–7.53)
in UCH (P< 0.0001 for group difference, P < 0.0001 for linear
trend). Differences persisted after adjustment for age, sex and
race, cardiovascular risk factors and their treatment and cardio-
vascular disease (P < 0.0001 for group difference, P < 0.0001
for linear trend).
Conclusions. MUCH is more strongly related to albuminuria
compared with cardiovascular damage as assessed by left ven-
tricular mass and PWV. A graded and an independent relation-
ship of blood pressure classiﬁcation status with albuminuria is
consistent with the hypothesis that renal mechanisms may be
more important than cardiovascular disease in mediating the
pathogenesis of MUCH.
Keywords: albuminuria, chronic kidney disease, left ventricu-
lar mass, masked hypertension, pulse wave velocity
INTRODUCTION
Cardiovascular disease frequently coexists with chronic kidney
disease (CKD) [1]. In the general population, it has long been
recognized that elevated blood pressure (BP) at home but nor-
mal BP in the clinic—masked hypertension—is associated with
arterial and ventricular damage [2]. It is now becoming increas-
ingly apparent that among treated hypertensives, elevated BP at
home but normal BP in the clinic—masked uncontrolled hyper-
tension (MUCH)—is associated with arterial and ventricular
damage [3–6]. Furthermore, MUCH is also associated with
lower estimated glomerular filtration rate (eGFR) and greater
proteinuria [3, 4, 6, 7]. What is less clear is whether MUCH is
associated with greater arterial, ventricular or renal damage. In
other words, whether MUCH is associated with greater end-
organ damage on the cardiovascular system or the kidney is
unclear.
The importance of this question lies in the fact that elevated
hypertension outside the office may be due to cardiovascular
damage which would be reflected by increased left ventricular
mass or increased arterial stiffness. On the other hand, it could
be related more strongly to renal damage as assessed by
albuminuria. If MUCH is associated more strongly with renal
damage, it would suggest that renal mechanisms may be opera-
tive in the genesis of MUCH. This would provide clues to the
understanding of MUCH and where efforts should be directed
to understand its pathogenesis; the pathogenesis of MUCH is
largely unknown.
This study explores the strength of the relationship of
MUCH with target organ damage. Target organ damage was
evaluated by measuring echocardiographic left ventricular mass
index (LVMI), aortic pulse wave velocity (PWV) and 24-h urine
for albuminuria.
MATERIALS AND METHODS
Details regarding the clinical characteristics of this cohort have
been previously published [8]. Briefly, this was a prospective
study of CKD patients stages 2 through 4 (eGFR defined using
the modification of diet in renal disease equation<90 mL/min/
1.73 m2 but >15 mL/min/1.73 m2). For those with stage 2
CKD, albuminuria (A2 or >300 mg/g creatinine) was required
for inclusion in the cohort. Those with an initial clinic BP of
140/90 mmHg or less were considered eligible and studied fur-
ther. However, about 10% of people with a single clinic BP of
140/90 mmHg were found to be hypertensive on further eval-
uation and were not excluded.
Healthy control veterans were selected to participate if they
did not have hypertension, diabetes, prior history of cardiovas-
cular disease, CKD and were not current smokers.
After obtaining a clinical history, performing a physical
examination and obtaining basic laboratory tests, measure-
ments of BP in the clinic (average of three visits) and by 24-h
ambulatory monitoring were performed as reported earlier.
Classification of hypertension
Masked uncontrolled hypertension (MUCH) was defined as
controlled clinic BP (<140/90 mmHg on average of three clinic
visits by oscillometric BP measurement) but elevated ambula-
tory BP [9–11]. Elevated ambulatory BP was defined as elevated
daytime (135/85 mmHg) BP. Those with clinic and daytime
ambulatory BP below thresholds were classified as controlled
hypertension (CH) and those with both above threshold were
defined as uncontrolled hypertension (UCH). To define day-
time and night-time, we used patient diaries.
The assessment of target organ damage was as follows.
Assessment of albuminuria
During the time of 24-h ambulatory BP monitoring, partici-
pants were asked to collect urine over the 24-h period that was
assayed for urine albumin by an immunoassay and urine creati-
nine using standard methods in the hospital laboratory. Results
are expressed as the ratio of albumin to creatinine (mg/mg) and
to approximate normal distribution and facilitate interpretation
of the ratio was log2-transformed prior to analysis.
Left ventricular mass measurements
Two-dimensional guided M-mode echocardiograms were
performed by an accredited technician during one of the study
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|visits (on the same day or at most within 30 days of ambulatory
BP measurement) with a digital cardiac ultrasound machine
(Cypress Acuson, Siemens Medical). The protocol specified
recording of at least 12 cycles of two-dimensional parasternal
long- and short-axis left ventricular (LV) views with optimal
orientation of the cursor beam used to derive additional M-
mode recordings. Each patient underwent six M-mode meas-
urements of interventricular septal thickness in diastole
(IVSTd), LV internal diameter in diastole (LVIDd) and systole
(LVIDs), LV posterior wall thickness in diastole (LVPWd) and
systole (LVPWs) and left atrial (LA) diameter using standards
of the American Society of Echocardiography [12]. LV mass
was calculated with a previously validated formula [13]:
LVmass ðgÞ ¼ 0:832
 ½ðIVSTdþ LVIDdþ LVPWdÞ3
 ðLVIDdÞ3 þ 0:60
PWV measurements
Arterial stiffness is best measured using the aortic PWV [14].
Accordingly, arterial stiffness was assessed by measuring aortic
PWV through direct visualization of the descending aorta with
the use of an echo-Doppler technique (Acuson Cypress,
Siemens Medical). Flow pulse was recorded by continuous
Doppler from the root of the left subclavian artery and just
proximal to the bifurcation of the abdominal aorta with simul-
taneous electrocardiographic recording [15]. The length of the
descending aorta was estimated by measuring the body surface
distance from the suprasternal notch to the recording site of the
aortic signal (near the umbilicus). Time elapsed from the peak
of the R wave to the foot of the systolic impulse was recorded
over six beats. The length of the descending aorta divided by the
difference between transit times was calculated to yield the
aortic PWV [15].
Statistical analysis
Baseline characteristics among groups were compared by
ANOVA for continuous variables and v2 tests for discrete varia-
bles such as sex, race, tobacco use and comorbidities.
To detect the association of BP classification status with tar-
get organ damage, unadjusted analyses were performed using
linear regression using BP classification as indicator variables.
The reference group was healthy controls. The P-value reported
is the test of the hypothesis that there is no association of BP
classification status with target organ damage. Adjustments
were performed in model 1 for age, sex and race and in model 2
for all variables in model 1 and cardiovascular risk factors and
their treatment including tobacco use, body mass index, diabe-
tes mellitus, serum cholesterol, number of antihypertensive
drugs used, angiotensin-converting enzyme (ACE) or angioten-
sin receptor blocker (ARB) use, calcium channel blocker (CCB)
use, beta blocker use, diuretic use, statin use and aspirin use and
model 3 was further adjusted for cardiovascular disease such as
myocardial infarction, coronary artery bypass graft, percutane-
ous coronary intervention, peripheral vascular disease and con-
gestive heart failure. An analysis for the presence of a linear
trend in coefficients from controls to CH, MUCH and UCH
was performed using orthogonal polynomials and reported as P
trend in Figures 2 and 3.
All statistical analyses were done with Stata 14.0 (Stata Corp,
College Station, TX, USA). Nominal level of statistical signifi-
cance was taken as two-sided P of 0.05.
RESULTS
Baseline characteristics of participants are given in Table 1. The
control group of 29 veterans did not have CKD, hypertension,
diabetes or cardiovascular disease. The CKD group of 287 veter-
ans predominantly had CH, 23% had MUCH and 9% had
UCH. As expected of a veteran population, participants were
older, mostly white men, and two-thirds were past smokers.
Notable was a high prevalence of diabetes mellitus and cardio-
vascular disease ascertained by a review of medical records. The
average eGFR was 44 mL/min/1.73 m2 and was similar among
CKD groups. All but four participants were receiving antihyper-
tensive drugs for BP control and the average number of antihy-
pertensive drugs used was 3.1. As expected, BP both in the
clinic and by ambulatory recordings was progressively higher
with progressive increments in hypertension severity.
The distribution of markers of target organ damage is
shown as box plots in Figure 1. Slight differences in medians
are seen for PWV, greater for LVMI, and the greatest for log
of the 24-h urine albumin/creatinine ratios. The distribution
of severity of albuminuria is shown as an inset in panel C.
Very high albuminuria (>300 mg/g creatinine, A2) was
present in none of the controls, 11% of CH, 44% of MUCH
and 48% of UCH. In contrast, normoalbuminuria (<30 mg/g
creatinine, A0) was present in 96% of controls, 61% of CH,
33% of MUCH and 9% of UCH. The relationship between BP
classification status and albuminuria was highly significant
(v2¼ 70.9, P< 0.0001).
Figure 2 shows the results of progressively adjusted models
for log2 urine albumin to creatinine ratio (UACR). The unad-
justed model is shown first. Given that the coefficients are in
log2 scale, compared with those of controls, the CH, MUCH
and UCH groups are approximately 5.3-, 30.7- and 64.4-fold
higher. The P-value for both among- group differences (P-
value) and a linear trend (P trend) is highly significant. Model 1
is age-, sex- and race-adjusted; model 2 is further adjusted for
cardiovascular risk factors and its treatment and model 3 is fur-
ther adjusted for cardiovascular disease as noted in Methods.
Progressive adjustment did not remove the statistical differen-
ces among groups and the linear trend remained highly signifi-
cant. Further adjustment for eGFR did not remove the
statistical significance among group differences (P < 0.0001) or
the linear trend (P< 0.0001).
Figure 3 shows the progressive adjusted models for LVMI
and PWV. In the case of LVMI, clear differences were seen in
the unadjusted model and model 1, and further adjustment
removed the statistical significance of the observations. In the
case of PWV, only the unadjusted model was significant. Any
adjustment increased the P-value to above the nominal level of
significance.
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DISCUSSION
That albuminuria is associated with greater ambulatory BP is
now well established. We first reported this observation in a
cross-sectional survey in which it was noted that the strength of
the relationship between proteinuria and systolic BP followed
the order: ambulatory > home > clinic [16]. Next, it was noted
that even slight degrees of albuminuria were associated with an
elevated ambulatory BP, independent of eGFR [17]. Large epi-
demiological surveys note that the odds of poorly controlled
hypertension are greater in the presence of albuminuria [18]. In
these surveys, eGFR does not emerge as an independent predic-
tor of poorly controlled hypertension. Among those with
CKD, after adjusting for baseline clinic BP, Minutolo et al.
reported that the odds of sustained hypertension diagnosed by
24-h ambulatory BP monitoring, compared with white coat
hypertension, are greater in the presence of albuminuria [19].
More recently, the Chronic Renal Insufficiency Cohort reported
that those with masked hypertension have nearly 2-fold higher
proteinuria compared with those with well-controlled hyper-
tension [3].
Our study provides a strong association between MUCH
and albuminuria. Furthermore, it extends the findings of the
above investigations by having an age- and sex-matched group
of normotensive veterans without CKD. By performing a trend
analysis, it demonstrates a graded relationship among CH,
MUCH and UCH and increasing severity of albuminuria even
after multiple adjustments. Thus, MUCH—the prevalence of
which was nearly one in four in this cohort—appears to be an
intermediate phenotype that lies between those with CH and
those with UCH. Our study also provided novel information
regarding the type of antihypertensive agent used and the pro-
pensity for MUCH.We found that CCB use was more common
in those with MUCH and diuretic use was less. This is not
Table 1. Baseline characteristics of the study sample
Clinical characteristic Control CKD CH MUCH UCH P-value
Number of participants, n (%) 29 287 193 (67.2%) 67 (23.3%) 27 (9.40%)
Age (years) 62.8 6 9.3 69.26 10 69.26 9.9 68.96 10.1 70.26 10.7 > 0.2
Male sex, n (%) 27 (93.1%) 281 (97.9%) 188 (97.4%) 66 (98.5%) 27 (100%) > 0.2
Race < 0.01
White, n (%) 25 (86.2%) 231 (80.4%) 165 (85.4%) 46 (68.6%) 20 (74.0%)
Black, n (%) 4 (13.7%) 47 (16.3%) 20 (10.3%) 20 (29.8%) 7 (25.9%)
Other, n (%) 0 (0%) 9 (3.13%) 8 (4.14%) 1 (1.49%) 0 (0%)
Weight (kg) 84.2 6 14.1 94.16 16.9 93.36 16.9 98.86 17.3 88.56 13.4 0.01
Body mass index (kg/m2) 26.9 6 3.5 30.96 4.6 30.66 4.6 32 6 4.7 30.16 4.2 0.07
Diabetes mellitus, n (%) 0 (0%) 185 (64.4%) 116 (60.1%) 49 (73.1%) 20 (74.0%) 0.09
Myocardial infarction, n (%) 0 (0%) 80 (27.8%) 57 (29.5%) 14 (20.8%) 9 (33.3%) > 0.2
Coronary artery bypass graft, n (%) 0 (0%) 62 (21.6%) 45 (23.3%) 10 (14.9%) 7 (25.9%) > 0.2
Percutaneous coronary intervention, n (%) 0 (0%) 73 (25.4%) 51 (26.4%) 16 (23.8%) 6 (22.2%) > 0.2
Congestive heart failure, n (%) 0 (0%) 52 (18.1%) 36 (18.6%) 9 (13.4%) 7 (25.9%) > 0.2
Peripheral vascular disease, n (%) 0 (0%) 62 (21.6%) 39 (20.2%) 14 (20.8%) 9 (33.3%) > 0.2
Smoking > 0.2
Never, n (%) 7 (24.1%) 48 (16.7%) 36 (18.6%) 8 (11.9%) 4 (14.8%)
Past, n (%) 22 (75.8%) 193 (67.2%) 130 (67.3%) 45 (67.1%) 18 (66.6%)
Current, n (%) 46 (16.0%) 27 (13.9%) 14 (20.8%) 5 (18.5%)
Laboratory tests
Estimated GFR (mL/min/1.73 m2) 94 6 13.9 43.86 15.4 44.96 15.7 41.86 15.2 40.66 12.6 0.19
Serum cholesterol (mg/dL) 187.86 34 158.96 43.7 158.86 45.9 158.66 41.7 160.46 32.3 > 0.2
Serum phosphorus (mg/dL) 3.26 .5 3.46 .6 3.46 .6 3.56 .6 3.56 .7 > 0.2
Antihypertensive drugs (n) 0 6 0 3.16 1.4 36 1.4 3.46 1.3 3.56 1.3 0.03
ACE inhibitors or ARBs, n (%) 0 (0%) 208 (72.4%) 144 (74.6%) 46 (68.6%) 18 (66.6%) > 0.2
Calcium channel blockers, n (%) 0 (0%) 129 (44.9%) 74 (38.3%) 39 (58.2%) 16 (59.2%) < 0.01
Beta blockers, n (%) 0 (0%) 196 (68.2%) 131 (67.8%) 44 (65.6%) 21 (77.7%) > 0.2
Diuretics, n (%) 1 (3.44%) 178 (62.0%) 110 (56.9%) 48 (71.6%) 20 (74.0%) 0.04
Statins, n (%) 13 (44.8%) 223 (77.7%) 150 (77.7%) 53 (79.1%) 20 (74.0%) > 0.2
Aspirin, n (%) 5 (17.2%) 190 (66.2%) 129 (66.8%) 46 (68.6%) 15 (55.5%) > 0.2
Multiple visit clinic systolic BP (mmHg) 113.36 6.7 120.36 15 113.96 11.6 127.66 9.4 147.66 6.7 < 0.0001
Multiple visit clinic diastolic BP (mmHg) 64.3 6 6.7 60 6 10.3 57.96 8.6 62.66 10.7 68.46 14.3 < 0.0001
Multiple visit clinic pulse rate (/min) 66.9 6 8.1 66.26 11.4 66.36 12 67.16 10.5 63.46 8.2 > 0.2
24-h ambulatory systolic BP (mmHg) 1176 6.9 126.96 14.2 119.76 9.5 1396 8.5 147.66 13 < 0.0001
24-h ambulatory diastolic BP (mmHg) 70.9 6 5.2 69.26 9.2 66.66 7.1 73.76 9 76.46 13.6 < 0.0001
24-h ambulatory pulse rate (/min) 69.9 6 8.6 69.26 10.3 68.86 10.4 70.66 10.1 68.26 10.2 > 0.2
Sleep ambulatory systolic BP (mmHg) 109.36 8.8 122.76 16.2 116.16 12.3 134.26 14.2 140.86 15.2 < 0.0001
Sleep ambulatory diastolic BP (mmHg) 64.2 6 6.9 65.36 9.9 62.96 7.7 69.76 10.8 71.46 14.4 < 0.0001
Sleep ambulatory pulse rate (/min) 63.7 6 9 66.16 10 65.56 10 67.86 9.7 65.76 10.8 > 0.2
Wake ambulatory systolic BP (mmHg) 121.66 7.2 129.36 14.5 121.86 9.3 141.96 7.5 151.66 13.7 < 0.0001
Wake ambulatory diastolic BP (mmHg) 74.9 6 5.4 71.46 9.5 68.76 7.5 76.26 9.3 79.36 13.7 < 0.0001
Wake ambulatory pulse rate (/min) 73.8 6 9.4 71 6 11 70.86 11.2 72.26 10.9 69.76 10.3 > 0.2
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widely appreciated, but it may be causally related [20]. We have
previously reported that CCB use is associated with a lower
clinic BP and a higher ambulatory recording [21]. This would
lead to a greater propensity for masked hypertension. The
reverse is the case for diuretics. We included diuretic use and
CCB use in our adjusted models, but excess albuminuria with
increasingly severe hypertension classification persisted. This
suggests that these antihypertensive agents per se are not suffi-
cient to account for excess albuminuria with increasingly severe
hypertension.
Whether a causal link exists between albuminuria and
MUCH cannot be answered by a cross-sectional investigation,
but if one exists then what could be the mechanisms? It is now
generally accepted that albuminuria is a marker of endothelial
dysfunction [22]. Albuminuria in the nephrotic range is associ-
ated with leakage of plasmin in the urine; this serine protease
can activate the epithelial sodium channel in the cortical collect-
ing duct and aggregate hypertension [23]. On the other hand,
albuminuria may simply be a marker of renal damage. If so, the
increasing severity of renal damage may lead to volume expan-
sion and impaired natriuresis that may provoke hypertension,
especially outside the clinic. Damage to the renal parenchyma
may lead to the accumulation of asymmetric dimethylarginine,
a potent inhibitor of nitric oxide synthase. This in turn would
reduce the production of the potent vasodilator nitric oxide that
may further provoke hypertension [24–27] and target organ
damage [28]. Accumulation of the potent vasoconstrictor endo-
thelin [29] and lack of production of the enzyme renalase [30,
31] that breaks down catecholamines, and adrenergic activation
seen even in earlier stages of CKD [32] may further provoke
hypertension. Whether any of the above mechanisms are of
pathophysiological importance for MUCH will require future
investigations.
Whereas a direct and strong link was seen between albumi-
nuria and MUCH, a weaker cross-sectional relationship
emerged between LVMI and MUCH. Even a weaker relation-
ship was seen between PWV and MUCH. Whereas it is now
well established that MUCH is associated with LVMI in the
general population [2, 33] and those with CKD [3, 4] and that
MUCH is associated with arterial damage in the general popula-
tion [2] and CKD [3, 34, 35], the recognition that the
albuminuria–MUCH relationship is much stronger further sug-
gests that MUCH may have a renal basis as discussed above.
The fact that the relationship between BP categories and LVMI
or PWV disappears after multiple adjustments suggests that
other factors besides elevated BP outside the clinic may account
for the target organ damage.
Limitations of the study include the following: participation
in the study was restricted to veterans who are older and are
predominantly men. Whether our findings apply to younger
FIGURE 1: Distribution of markers of target organ damage by BP classiﬁcation status. C reﬂects age- and sex-matched normotensive veterans
without CKD or known cardiovascular disease. The remaining groups have CKD and progressively darker shades of gray are those with con-
trolled hypertension (CH), masked uncontrolled hypertension (MUCH) and uncontrolled hypertension (UCH). The horizontal line in the box
denotes the median, the box itself the 25th and 75th percentiles of the observations; the whiskers are the upper and lower adjacent values that
are 1.5 times the interquartile range and the dots are outliers. Panel C represents the distribution of urine albumin to creatinine ratio in 24-h
urine collection. The horizontal lines are thresholds of high albuminuria (A1) and very high albuminuria (A2). The number of participants (n
and %) with increasing levels of albuminuria is shown in the inset table at the top of the ﬁgure in panel C.
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|people and women will need future studies. The study is cross-
sectional in nature and can only detect associations. Whether
the relationships are causal is unclear. There are several
strengths to our study: our study used 24-h ambulatory blood
pressure monitoring, the gold-standard method to diagnose
out-of-office hypertension. Our study was prospective, and it
carefully collected information on Doppler-assessed PWV,
echocardiographic left ventricular mass and 24-h urine albumin
collections solely for the purposes of the study. All measure-
ments were concurrent, unlike some of the earlier reports where
median time elapsed between target organ damage assessment
and 24-h ambulatory BP measurement exceeded 300 days [3].
FIGURE 2: Forest plot of regression coefﬁcients and their 95% conﬁdence intervals for progressively adjusted models. Unadjusted model
denotes the log2 of 24-h urine albumin/creatinine ratio as the dependent variable and the BP classiﬁcation categories as the independent varia-
ble. The reference category of non-CKD control group is compared with those with controlled hypertension (CH), masked uncontrolled hyper-
tension (MUCH) and uncontrolled hypertension (UCH). The P-value represents whether the independent variable of BP classiﬁcation is
signiﬁcantly different from 0. The P trend denotes whether there is a linear relationship in progressively severe hypertension categories. Model
1 is adjusted for age, sex and race, model 2 for cardiovascular risk factors and their treatment and model 3 is adjusted for cardiovascular disease
as noted in Methods.
FIGURE 3: Forest plot of regression coefﬁcients and their 95% conﬁdence intervals for progressively adjusted models for left ventricular mass
index (LVMI, left panel) and pulse wave velocity (PWV, right panel). The remainder of the legend is as in Figure 2.
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|Furthermore, having a group of control age- and sex-matched
veterans without CKD increased the validity of the findings. A
large number of clinical characteristics were collected prospec-
tively to facilitate adjustments in statistical models and
interpretation.
In conclusion, among patients with CKD, nearly all of whom
were taking antihypertensive medications, a graded relationship
was found between BP categories and severity of target organ
damage in general. MUCH was most strongly related to renal
damage—not when assessed by eGFR—but when assessed by
albuminuria. MUCH was less strongly related to LVMI and
PWV. These results are consistent with the notion that kidney
damage may have a central role in the pathogenesis of MUCH.
Further investigations into the mechanisms centered on the
renal pathogenesis of MUCH are warranted. Finally, the strong
association of MUCH with albuminuria may in part explain the
mechanism of the ability of albuminuria to predict adverse out-
comes [36].
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ABSTRACT
Background. Chronic hepatitis C virus (HCV) infection is the
most common chronic liver disease in patients with end-stage
renal disease (ESRD). Over the last few years, second-
generation direct-acting antivirals have been revolutionary in
the treatment of hepatitis C, and sofosbuvir (SOF) is the back-
bone of most modern treatment strategies. Since SOF is elimi-
nated through the kidney, the aim of this multicentre retrospec-
tive study was to assess its antiviral efﬁcacy and safety in HCV-
infected patients with severe renal failure [including haemodial-
ysis (HD) patients].
Methods. Fifty patients (36 males, mean age6 standard devia-
tion 60.56 7.5 years) with chronic HCV infection (G1: 28/56%,
cirrhosis: 27/54%) and severe renal failure [i.e. MDRD esti-
mated glomerular ﬁltration rate (eGFR) <35 mL/min], includ-
ing 35 on HD, were enrolled. Antiviral treatment consisted
of SOF/ribavirin (RBV) (n¼ 7), SOF/RBV/pegylated interferon
(n¼ 2), SOF/daclatasvir6 RBV (n¼ 30) or SOF/simeprevir6
RBV (n ¼ 11) for 12 or 24 weeks. A reduced dose of SOF (400
mg three times a week or 400 mg every other day) was given to
all HD patients. Initial dose of RBV (n ¼ 12) ranged from 400
to 4200 mg/week.
Results.On an intent-to-treat-based analysis, sustained virolog-
ical response rate was 86% at 12 weeks. During therapy, haemo-
globin levels were not signiﬁcantly modiﬁed, but recombinant
erythropoietin (rEPO) dose signiﬁcantly increased in patients
treated with RBV. Two patients (4%) required blood transfu-
sion. No patient had treatment discontinuation due to side
effects. Dose of RBV was reduced in two patients (16.7%) during
antiviral therapy. Dose of SOF was reduced in two non-HD
patients because of side effects. In non-HD patients, median
eGFR was not signiﬁcantly modiﬁed during treatment.
Conclusions. Our results strongly suggest that SOF-based anti-
viral therapy, with a reduced dose of SOF, is safe and effective
for the treatment of HCV patients with ESRD, including HD
patients.
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